Visualitza per autor "Simonelli, Matteo"
Ara mostrant els elements 1-5 d 5
-
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Robbrecht, Debbie; Grob, Jean-Jacques; Bechter, Oliver; Simonelli, Matteo; Doger, B.; Borbath, Ivan; Doger, B; GARRALDA, Elena (Wiley, 2024-02) -
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Yap, Timothy A.; Vieito Villar, Maria; Baldini, Capucine; Sepúlveda, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo (American Association for Cancer Research, 2021-12) -
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
Garralda Cabanas, Elena; Eskens, Ferry; Gil-Martin, Marta; Yen, Chia-Jui; Santoro, Armando; Simonelli, Matteo (Elsevier, 2022-10) -
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
Santoro, Armando; Su, Wu-Chou; Navarro Mendivil, Alejandro; Yang, James C. H.; Ardizzoni, Andrea; Felip Font, Enriqueta; Simonelli, Matteo (Elsevier, 2022-04) -
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Vieito Villar, Maria; De Vos, Filip; Marjolein Geurts; Lorenzi, Elena; Moreno, Victor; Simonelli, Matteo (Oxford University Press, 2022-01)